Abstracts tagged "proteomics"

Abstract Number: 1780 • ACR Convergence 2023
Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study
Jiri Baloun¹, Kristyna Bubova¹, Aneta Pekacova², Lucia Ondrejcakova³, Vladimir Cervenak⁴, Monika Gregova⁵, Sarka Forejtova⁵, Jana Horinkova¹, Jindriska Gatterova⁶, Michal Tomcik⁷, Jiri Vencovsky⁷, Karel Pavelka⁸ and Ladislav Senolt⁹, ¹Institute of Rheumatology, Prague, Czech Republic, ²First faculty of medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Department of Medical Imaging, St Anne's University Hospital, and Faculty of Medicine, Masaryk University, Brno, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic, ⁶Rheumatology Institute, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: Axial spondyloarthritis (AxSpA) is a frequent inflammatory disease with a significant impact on a patient's quality of life. Therefore, early diagnosis and recognition of…
Abstract Number: 0735 • ACR Convergence 2023
Deep Immunophenotyping Reveals Circulating Activated Lymphocytes in Individuals at Risk for Rheumatoid Arthritis
Jun Inamo¹, Joshua Keegan², Alec Griffith², Tusharkanti Ghosh³, Alice Horisberger², Kaitlyn Howard², John Pulford², Ekaterina Murzin², Brandon Hancock², The Accelerating Medicines Partnership SLE/RA⁴, Marie Feser⁴, Jill Norri⁵, Anna Helena Jonsson⁶, Ye Cao⁷, William Apruzzese⁸, S. Louis Bridges⁹, Vivian Bykerk¹⁰, Susan Goodman⁹, Laura Donlin⁹, Gary S Firestein¹¹, Harris Perlman¹², Joan Bathon¹³, Laura Hughes¹⁴, Darren Tabechian¹⁵, Andrew Filer¹⁶, Costantino Pitzalis¹⁷, Jennifer Anolik¹⁵, Larry Moreland¹⁸, Joel Guthridge¹⁹, Judith James¹⁹, Michael Brenner², Soumya Raychaudhuri⁶, Jeffrey Sparks²⁰, Jennifer Seifert²¹, Michael Holer⁴, Kevin Deane⁴, James Lederer², Deepak Rao⁶ and Fan Zhang²², ¹University of Colorado School of Medicine, Aurora, CO, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Colorado School of Public Health, Denver, CO, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Department of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Department of Medicine, University of California San Diego, La Jolla, CA, ¹²Northwestern University, Chicago, IL, ¹³Columbia University, New York, NY, ¹⁴University of Alabama at Birmingham Medicine, Birmingham, AL, ¹⁵University of Rochester Medical Center, Rochester, NY, ¹⁶University of Birmingham, Birmingham, United Kingdom, ¹⁷Queen Mary University of London, London, United Kingdom, ¹⁸University of Colorado, Denver, CO, ¹⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ²¹The Accelerating Medicines Partnership RA/SLE Network, ²²University of Colorado, Aurora, CO

Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no effective prevention strategies. Single-cell technologies have been used to investigate established RA heterogeneity…
Abstract Number: 1795 • ACR Convergence 2023
Multi-Omics Analyses Identify Metabolic Pathways That Differentiate Psoriatic Arthritis from Psoriasis
Chiara Pastrello¹, Darshini Ganatra², Max Kotlyar¹, Nikita Looby², Quan Li³, Lihi Eder⁴, Dafna Gladman⁵, Proton Rahman³, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁴Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁷Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a form of inflammatory arthritis that occurs in patients with cutaneous psoriasis. Due to the lack of clinically useful diagnostic…
Abstract Number: 0850 • ACR Convergence 2023
Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis
Andrea Fava¹, Mohamed G. Atta¹, Jose Monroy-Trujillo², Derek Fine², Daniel Goldman³, Izmirly peter⁴, H Michael Belmont⁵, the Accelerating Medicines Partnership in RA/SLE⁶, Jill Buyon⁷ and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴NYU, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶Multiple, Multiple, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: One third of lupus nephritis (LN) patients develop irreversible kidney damage despite achieving a clinical response based on resolution of proteinuria. Furthermore, per protocol…
Abstract Number: 1829 • ACR Convergence 2023
Blood-derived Extracellular Vesicles as Potential Diagnostic Biomarker in Fibromyalgia Syndrome
Gilad Halpert, Daniel Yechiali, liel Katbi, Eri Govrin, Boris Guilbord, Ori Segal and Howard AMITAL, Sheba Medical Center, Ramat Gan, Israel
Background/Purpose: The Fibromyalgia syndrome (FMS) is a global chronic pain condition, which affects approximately 2–6% of the population. The underlying mechanism of FMS is unclear…
Abstract Number: 1087 • ACR Convergence 2022
Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach
Zachary Wallace¹, Amit Joshi¹, Xiaoqing Fu¹, Claire Cook¹, yuqing zhang² and Hyon Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with excess morbidity and mortality. Identifying novel biomarkers may reveal new therapeutic targets and clinically useful biomarkers of disease…
Abstract Number: 1127 • ACR Convergence 2022
Unsupervised Clustering Analysis of the Serum Proteome Identifies Systemic Sclerosis Patients with Distinctive Clinical Features
Chary Lopez-Pedrera¹, Rafaela Ortega-Castro¹, Tomás Cerdó², Pilar Font¹, María Martinez-Monllor³, Laura Muñoz-Barrera¹, Ismael Sánchez-Pareja², María Carmen Ábalos-Aguilera³, Nuria Barbarroja¹, Eduardo Collantes¹, María Ángeles Aguirre-Zamorano⁴ and Carlos Pérez-Sánchez¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁴Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain
Background/Purpose: Systemic sclerosis (SSc) is an heterogeneous autoimmune disease. There is an unmet need of biomarkers for diagnosis, progression and therapeutic response.This study aimed to…
Abstract Number: 1129 • ACR Convergence 2022
Integrated High-throughput Proteomics and Machine Learning Analysis in Systemic Lupus Erythematosus Patients Identify Distinctive Clinical Profiles and Novel Biomarkers Related to Cardiovascular Risk and Lupus Nephropathy
Chary Lopez-Pedrera¹, Tomás Cerdó², María Ángeles Aguirre-Zamorano³, Laura Muñoz-Barrera¹, Ismael Sánchez-Pareja², Pilar Font¹, María Carmen Ábalos-Aguilera⁴, Pedro Ortiz-Buitrago⁴, Nuria Barbarroja¹, Eduardo Collantes¹, Rafaela Ortega-Castro¹ and Carlos Pérez-Sánchez¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁴Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a remarkably heterogeneous autoimmune disease. At present, our knowledge of serum protein patterns related to cardiovascular (CV) risk and…
Abstract Number: 1135 • ACR Convergence 2022
Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
Shudan Wang¹, Anna Broder², Daming Shao³, Vartika Kesarwani⁴, Brianna Lally⁵, Masako Suzuki⁶, J. Michelle Kahlenberg⁷, Jennifer Aguilan⁶ and Simone Sidoli⁶, ¹Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ²Hackensack University Medical Center, Hackensack, NJ, ³Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ⁴University of Connecticut, Farmington, CT, ⁵University of Wisconsin Hospitals and Clinics, Madison, WI, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: The complement system has an important and underrecognized role in mediating tubulointerstitial disease in lupus nephritis (LN). The omics big data allows for identifying…
Abstract Number: 1163 • ACR Convergence 2022
Proteomic Investigation to Identify Urinary Biomarker for Ankylosing Spondylitis
Ji-Hyun Lee¹, Jeesoo Kim², Sang-Hyon kim¹, Jong‑Seo kim² and Chang-Nam son¹, ¹Keimyung University, Dalseo-gu, Daegu, Republic of Korea, ²seoul national university, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the spine and peripheral joints, and the exact etiology is still unknown. Diagnosis…
Abstract Number: 0360 • ACR Convergence 2022
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Mark Lazarus¹, Paul Newcombe¹, Richard A. Furie², Philip Brohawn³, Wendy White³, Dominic Sinibaldi³, Nicola Ferrari¹, Raj Tummala³, Hussein Al-Mossawi¹, Edward Vital⁴, Eric F. Morand⁵, Daniel Muthas⁶ and Madhu Ramaswamy³, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³AstraZeneca, Gaithersburg, MD, ⁴University of Leeds, Leeds, England, United Kingdom, ⁵Monash University, Melbourne, Australia, ⁶AstraZeneca, Gothenburg, Sweden
Background/Purpose: Phase 2/3 clinical trials in patients with moderate to severe SLE have demonstrated that anifrolumab, a monoclonal antibody blocking IFNAR1, produced better clinical outcomes…
Abstract Number: 1176 • ACR Convergence 2022
Immunoglobulins G from Systemic Sclerosis Patients May Alter the Secretome of Dermal Fibroblasts
Aurélien Chepy¹, Marie Duhamel², Solange Vivier³, lucile Guilbert³, Eric Hachulla⁴, Sylvain Dubucquoi³, David Launay³, Michel Salzet² and Vincent Sobanski³, ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ²Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, ³Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, ⁴University of Lille, LILLE, France
Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc).Recently, it has been shown that immunoglobulins G (IgG) from SSc promoted a proinflammatory and profibrotic phenotype…
Abstract Number: 0386 • ACR Convergence 2022
Quantitative Proteomic Screening Uncovers Diagnostic and Monitoring Serum Biomarkers of Ankylosing Spondylitis
Mark Hwang¹, Jessica Castillo², kamala Vanarsa², Jim Zheng³, Shervin Assassi⁴, Chandra Mohan² and John Reveille⁵, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²University of Houston, Houston, TX, ³UTHealth School of Bioinformatics, Houston, TX, ⁴McGovern Medical School, University of Texas, Houston, TX, ⁵University of Texas McGovern Medical School, Houston, TX
Background/Purpose: We sought to discover novel serum biomarkers of ankylosing spondylitis (AS) for diagnosis and monitoring disease activity. Methods: We used biologic-treatment naïve AS and…
Abstract Number: 1537 • ACR Convergence 2022
Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis
Line Iversen¹, Ole Østergaard², Tina Friis³, susanne Ullman⁴, Søren Jacobsen⁵ and Jesper Olsen², ¹Department of Dermatology, Odense University Hospital., Odense, Denmark, ²Novo Nordisk Foundation Center for Protein Research, Copenhagen University, Copenhagen, Denmark, ³Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, ⁴Department of Dermatology, Bispebjerg, Copenhagen University Hospitals, Copenhagen, Denmark, ⁵Department of Rheumatology, Rigshospitalet, Copenhagen University Hospitals, Copenhagen, Denmark
Background/Purpose: In the current work, we used a mass spectrometry based proteomics workflow to analyze isolated plasma microvesicles from systemic sclerosis (SSc) patients and from…
Abstract Number: 0471 • ACR Convergence 2022
Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)
Lisa Christ¹, Andrea Gloor², Florian Kollert¹, Timo Gaber³, Frank Buttgereit³, Stephan Reichenbach⁴ and Peter Villiger⁵, ¹Department of Rheumatology and Immunology, University of Bern, Inselspital, Bern, Switzerland, ²Department of Internal Medicine, University of Bern, Inselspital, Bern, Switzerland, ³Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ⁴University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland, ⁵Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland
Background/Purpose: Measuring disease activity in patients with giant cell arteritis (GCA) remains challenging since appropriate biomarkers are missing, particularly, if tocilizumab (TCZ) is prescribed which…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].